Surv Biopharma
Kagoshima, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $1B
Overview
A Kagoshima University spin-out developing survivin-promoter-driven oncolytic viruses and gene therapy vectors for oncology and metabolic diseases.
OncologyImmunology
Technology Platform
Engineered adenoviral vectors utilizing tissue-specific promoters, primarily the cancer-selective survivin promoter for oncolytic viruses and vectors encoding growth factors like HGF for in vivo gene therapy.
Opportunities
Expansion of the survivin-promoter platform to additional cancer types and combination therapies, and leveraging the gene therapy vector platform for other growth factors or immunomodulatory proteins in metabolic and inflammatory diseases.
Risk Factors
Clinical development risks for oncolytic viruses including efficacy, immune response, and manufacturing; competition in the crowded oncolytic virotherapy space; and dependence on partnership success for late-stage development and commercialization.
Competitive Landscape
Competes with other oncolytic virus developers (e.g., Amgen/T-VEC, DNAtrix, Oncolytics Biotech) and gene therapy companies; differentiation lies in the survivin-promoter specificity and academic foundation from Kagoshima University's research.